- Details
- Bob Hollander shares how his fascination with wine began during medical school, leading him through Napa and eventually to create his own award-winning blends. However, his life took an unexpected turn when, after a series of missed diagnoses, he was diagnosed with metastatic prostate cancer. Instead of succumbing to adversity, Dr. Hollander transformed his love for wine into a philanthropic endea...
|
- Details
- Logan Briggs joins Alicia Morgans to delve into his research investigating the impact of androgen receptor-targeted drugs on cognitive function in prostate cancer patients. Dr. Briggs explains his team's use of VigiBase, a global pharmacovigilance database, to assess the neurotoxic effects of various hormone therapies, a relevant topic considering that approximately half of the 1 in 8 men diagnose...
|
- Details
- Alicia Morgans interviews Herb Geller about a study into peer-led support groups for prostate cancer patients. Dr. Geller explains the AnCan model which is focused on online peer-led support groups catering to different types of prostate cancer. These groups provide a platform for patients to share their experiences, ask questions, and gain information without additional irrelevant data. As a part...
|
- Details
- Gary Deng discusses his book "The Wellness Principles" in a conversation with Alicia Morgans. The book, which Dr. Deng describes as a wellness guide rather than a cookbook, is aimed at improving the quality of life for cancer patients by encouraging healthy lifestyles. Dr. Deng argues against extreme diet plans, instead promoting balanced, quick-to-make, and delicious meals. In particular, he shar...
|
- Details
- Jacob Berchuck shares his insights with Alicia Morgans about his groundbreaking research on racial disparities in prostate cancer between African American and European American men. Dr. Berchuck's study explores the androgen receptor cistrome and its differing effects on prostate cancer biology. He identifies increased androgen receptor binding at genes associated with lipid metabolism in African...
|
- Details
- Alexander Wyatt delves into his team's cutting-edge research on circulating tumor DNA (ctDNA) in relation to prostate cancer. This innovative study, published in Nature, elucidates the diversity and potential utility of ctDNA, found in the bloodstream, for understanding disease progression and characteristics. By developing algorithms to differentiate various ctDNA populations, they shed light on...
|
- Details
- Noel Clarke delivers a comprehensive discussion about the STAMPEDE trial model, focusing on its innovative approach to prostate cancer treatment in the UK. He elaborates on the multi-arm, multi-stage (MAMS) trial design, emphasizing its flexibility and efficiency, and the collaboration with large data sets like the National Prostate Cancer Audit. Dr. Clarke highlights significant results, such as...
|
- Details
- In this discussion between Alicia Morgans and Alexander Wyatt, the two delve into the complexities of using circulating tumor DNA (ctDNA) in the treatment of prostate cancer. Dr. Wyatt explains the advantages of ctDNA in the metastatic setting, highlighting its minimally invasive nature and ease of collection compared to tissue biopsy. He emphasizes the importance of timing and patient selection i...
|
- Details
- Marzia Del Re discusses the complexity of tumor heterogeneity in prostate cancer, focusing on predictive biomarkers of resistance and response to therapy. Dr. Del Re emphasizes the high heterogeneity of prostate cancer from clinical, morphological, and molecular perspectives, highlighting the role of genetic and epigenetic alterations. She explores technological advancements like next-generation s...
|
- Details
- Andrea Alimonti discusses the challenges and advancements in the understanding and treatment of castration-resistant prostate cancer (CRPC). Dr. Alimonti highlights his team's efforts to comprehend the mechanisms of CRPC initiation and progression and explores potential therapies that could reverse or treat CRPC using anti-tumor immune responses. He emphasizes his team's contributions to the field...
|
